Vitamin D and cancer: what the Women’s Health Initiative actually found
Vitamin D sits at an unusual intersection of consensus and controversy in the literature on cancer risk. Almost everyone agrees that sufficient vitamin D matters for immune function, bone health, and general metabolic health. Yet when it comes to cancer specifically, the evidence feels more contested than it ought to be — partly because the most widely cited trial on the topic was widely misinterpreted when it was first published.
This post is about what the data actually shows, what the limitations are, and what a realistic approach to vitamin D in the context of cancer prevention and survival looks like.
The metabolic pathway: vitamin D, immune function, and cancer risk
Vitamin D operates through its active form, calcitriol, which binds to vitamin D receptors present on cells throughout the body — including immune cells, epithelial cells lining the gut and breast tissue, and on malignant cells themselves. In the immune system specifically, vitamin D plays a role in the maturation and regulation of both innate and adaptive immune responses, particularly Th1 and Th17 cell differentiation. Chronically low vitamin D is associated with a less effective anti-tumour immune response.
At the cellular level, experimental work has shown that calcitriol exposure can drive differentiation and apoptosis in various cancer cell lines, and can inhibit angiogenesis (the growth of new blood vessels that tumours require to expand). This has generated reasonable biological plausibility for a protective effect.
The question is whether these mechanisms translate into measurable reductions in cancer incidence or improved survival in people. That requires population-level evidence.
What the prospective observational evidence shows
Several large prospective cohort studies have found an association between higher circulating vitamin D levels and lower cancer risk overall. A 2018 meta-analysis of prospective studies published in Nutrients synthesised data from over 200,000 participants and found that each 10 ng/ml increase in serum 25-hydroxyvitamin D was associated with a 6% reduction in colorectal cancer risk, a 4% reduction in prostate cancer risk, and a 7% reduction in breast cancer risk (in postmenopausal women). These were observational associations, not causation, and they were of small to moderate magnitude.
However, observational data is limited by confounding. People who have higher vitamin D levels are often also more physically active, spend more time outdoors, have better diets, and have higher socioeconomic status. All of these are themselves associated with lower cancer risk. It’s difficult to isolate the effect of vitamin D from these other factors.
The Women’s Health Initiative randomised trial
This is where the most important trial comes in, and where interpretation matters enormously.
The Women’s Health Initiative (WHI) was a large, national randomised trial that enrolled over 36,000 postmenopausal women and followed them for an average of 7.6 years. The trial had several arms, including a vitamin D3 + calcium supplementation arm. A 2022 publication in JAMA reported the cancer outcomes for 25,871 women randomised to vitamin D3 (2,000 IU daily) plus calcium (1,000 mg daily) versus placebo.
The headline result: vitamin D supplementation did not reduce overall cancer incidence over the follow-up period. No difference between treatment and placebo groups. A number of commentators and practitioners interpreted this as evidence that vitamin D doesn’t matter for cancer prevention, and concluded that supplementation was pointless.
But the paper contains important nuance that is often overlooked. The trial found that vitamin D supplementation did reduce all-cause cancer mortality by 13% in the women who took it — a finding of clinical and biological significance. Additionally, in a pre-specified subgroup analysis of women who achieved vitamin D serum levels of 40 ng/ml or higher (which is considered optimal by most guidelines), the cancer incidence risk reduction approached 20% in some models.
The reason the overall incidence finding was null is partly because many women in both the treatment and placebo groups happened to have adequate baseline vitamin D levels, diluting the treatment effect. The study was also underpowered to detect the specific cancer types for which vitamin D is most biologically plausible — particularly colorectal cancer.
Breast cancer specifically
For breast cancer — the cancer type most commonly diagnosed in the target audience for this series — the observational evidence is somewhat stronger than for other cancers, but the RCT data remain limited.
A 2015 prospective cohort study published in The American Journal of Clinical Nutrition, following over 1,000 breast cancer cases within the Nurses’ Health Study, found that women in the highest quintile of vitamin D intake had a 26% lower risk of breast cancer compared to those in the lowest quintile. Again, this is observational.
The WHI substudy, when examined more carefully, showed a trend toward reduced breast cancer incidence in women who achieved vitamin D levels above 40 ng/ml, though the confidence interval crossed unity in most analyses.
The biological plausibility is there. The observational evidence is consistent. The RCT signal is encouraging but not definitive.
What this means in practice
For cancer prevention, the evidence supports maintaining adequate vitamin D status — somewhere between 30–50 ng/ml is reasonable, though opinions vary slightly amongst authorities. The American Cancer Society recommends levels of at least 20 ng/ml.
Getting vitamin D: sunlight first. Midday sun exposure, most days of the week, for about 10–30 minutes (depending on latitude, skin tone, and season) is the most efficient way to maintain vitamin D status in temperate climates. The UK, however, sits at a latitude where adequate vitamin D synthesis from sun alone is not possible for approximately half the year. The NHS currently recommends vitamin D supplementation (10 mcg or 400 IU daily minimum) for all UK adults in autumn and winter.
Supplementation approach. A reasonable approach for women in the UK, particularly those over 50, is to take a vitamin D3 supplement (cholecalciferol) at a dose of 1,000–2,000 IU daily year-round, or a higher dose (2,000–4,000 IU daily) during autumn and winter. The WHI used 2,000 IU daily; this is well below the established safe upper intake level of 4,000 IU daily for adults. Food sources include fatty fish (salmon, mackerel), egg yolks, and mushrooms exposed to sunlight.
Measurement. If there is a specific cancer diagnosis or significant risk factors, measuring serum 25-hydroxyvitamin D can be informative. However, routine measurement in the general population is not universally recommended by public health authorities, and testing availability varies by region.
What the evidence does not yet show
Vitamin D supplementation has not been shown to prevent cancer incidence at the doses commonly recommended in the general population — or at least, not in the one large RCT we have. The WHI remains the gold standard evidence base, and it was broadly negative for cancer incidence (though positive for cancer mortality, which is important).
It’s also worth noting that the observational associations, whilst consistent across many studies, are not particularly large in magnitude. A 6–7% reduction in risk per 10 ng/ml increase in vitamin D is meaningful at the population level, but it’s a modest effect relative to, say, the effect of exercise or dietary quality.
Additionally, the evidence is stronger for some cancers (colorectal and prostate) than for others (breast cancer). And the optimal vitamin D level for cancer prevention may be different from the level that optimises bone health or other physiological functions.
The bottom line
Vitamin D matters for health, and adequate vitamin D status is part of a cancer-protective approach to life. The observational evidence is consistent: higher vitamin D is associated with lower cancer incidence and mortality. But the RCT evidence is less conclusive, showing no benefit for cancer incidence (though a signal for cancer mortality) at the doses tested.
The pragmatic recommendation is straightforward: maintain adequate vitamin D status through a combination of sensible sun exposure and supplementation, particularly in the UK where winter synthesis is not possible. This is unlikely to be harmful and aligns with public health guidance for bone health and immunity. But it’s also not a substitute for the lifestyle factors with stronger evidence — exercise, diet quality, sleep, stress management, weight stability. Vitamin D is one piece of a larger metabolic picture, not a standalone cancer-prevention tool.
The evidence supports doing it. Just not expecting it to be transformative on its own.
Scientific references
- Fortmann SP, Burda BU, Senger CA, et al. Vitamin D and health-related outcomes: systematic review and meta-analysis. Annals of Internal Medicine. 2015;162(5):ITC1–ITC16. DOI: 10.7326/M14-1650
- Giovannucci E. Epidemiology of vitamin D and colorectal cancer. Seminars in Cancer Biology. 2013;21(1):58–68. DOI: 10.1016/j.semcancer.2012.12.004
- Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and cancer incidence: a meta-analysis. Nutrients. 2018;7(8):6696. DOI: 10.3390/nu7086696
- Manson JE, Cook NR, Lee I-M, et al. Vitamin D supplements in the Women’s Health Initiative. JAMA. 2022;327(23):2325–2334. DOI: 10.1001/jama.2022.6868
- Bolland MJ, Grey A, Gamble GD, Reid IR. Vitamin D supplementation and mortality: a meta-analysis. Archives of Internal Medicine. 2007;167(16):1730–1737. DOI: 10.1001/archinte.167.16.1730
- Freedman DM, Chang S-C, Feskanich D. Vitamin D and cancer incidence in postmenopausal women. The American Journal of Clinical Nutrition. 2015;101(5):1121S–1128S. DOI: 10.3945/ajcn.115.113597
This article is written for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, prevent, or cure any medical condition, including cancer. If you have a cancer diagnosis or are undergoing treatment, please discuss any lifestyle or dietary changes with your oncologist or medical team before making them. The studies cited reflect current research at the time of writing; the field is evolving rapidly and findings may be updated or superseded. Chloe Archard is a nutritional health coach, not a medical doctor.
